Since January of 2010, the seventh edition of UICC tumor node metastasis (TNM) Classification, which has recently been revised, has been applied to almost all cases of malignant tumors. Compared to previous editions, the merits and demerits of the current revisions were analyzed. Many revisions have been made for criteria for the classification of lymph nodes. In particular, all the cases in whom the number of lymph nodes is more than 7 were classified as N3 without being differentiated. Therefore, the coverage of the N3 was broad. Owing to this, there was no consistency in predicting the prognosis of the N3 group. By determining the positive cases to a distant metastasis as TNM stage IV, the discrepancy in the TNM stage IV compared to the sixth edition was resolved. In regard to the classification system for an esophagogastric (EG) junction carcinoma, it was declared that cases of an invasion to the EG junction should follow the classification system for esophageal cancer. A review of clinical cases reported from Asian patients suggests that it would be more appropriate to follow the previous editions of the classification system for gastric cancer. In addition, in the classification of the TNM stages in the overall cases, the discrepancy in the prognosis between the different stages and the consistency in the prognosis between the same TNM stages were achieved to a lesser extent as compared to that previously. Accordingly, further revisions are needed to develop a purposive classification method where the prognosis can be predicted specifically to each variable and the mode of the overall classification can be simplified. 
Introduction
Tumor node metastasis (TNM) staging provides guidance for selecting the optimal treatment modalities. It also provides information on the prognosis for both physicians and patients. Furthermore, it is also used as a tool by which the treatment outcomes can be compared at hospitals and in different countries.
Disease staging based on the TNM classification currently provides a basis for staging almost all cases of a malignant tumor.
This staging method is amended continuously and revised over time
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
as new diagnostic or treatment methods have been developed. In the disease staging system, it is essential to determine if consistency can be acquired between the groups for which the same disease stage was determined and how the differentiation could be made between groups for which a different disease stage was determined.
In addition, the applicability should be considered from a practical perspective. That is, it would be ideal to develop the staging system in such a manner that the specificity to each category should be assured and the overall classification should be simplified. In this regard, this study assessed the seventh edition of TNM staging. In other words, it was recommended that lymph nodes be classified based on the anatomical location. On the other hand, the fifth edition recommends that the lymph nodes be classified based on the number of lymph nodes with a metastasis. Major revisions on the current seventh edition include the following:
(1) Changes in the methods for classifying lymph nodes (2) Changes in the definition of TNM stage IV (3) Changes in the application of the disease staging to the esophago-gastric junction (4) The classification of positive cases to a peritoneal washing cytology to a distant metastasis.
Given this background, this study analyzed the significance of these changes and examined the matters that need to be considered in the future classification of the disease stage.
The Scope of the Classification of Lymph Nodes with Metastasis
A revision was made for the definitions on the seventh edition when they were based on the number of lymph nodes observed on the fifth and the sixth edition. In other words, in the seventh edition, which unlike the previous classifications in that the number of lymph nodes with a metastasis of 1~6, 7~15 and ≥16 were classified as N1, N2 and N3, respectively, those in which the number of lymph nodes with a metastasis was 1~2, 3~6, 7~15 and ≥16 were classified as N1, N2, N3a and N3b, respectively. N3a and N3b were classified as the same stage. According to Ha et al., (2) there was a significant difference in the survival rate between N3a and N3b. In particular, in the seventh edition, all cases with a metastasis in more than 7 lymph nodes were classified as N3.
Compared to N1 or N2, there was a wider standard deviation in the number of lymph nodes with a metastasis (N1: 0.49, N2: 1.10 and N3: 13.77). This indicates that there is great variability in the number of lymph nodes with a metastasis in patients who belong to the N3 group. Based on the cut-off value of the number of lymph nodes with a metastasis of 30, N3 was subclassified into N3a (the number of lymph nodes with metastasis: 7~15), N3b (the number of lymph nodes with metastasis: 16~30) and N3c (the number of lymph nodes with metastasis: ≥31). This was followed by an analysis of the survival rate between the three subgroups in those patients with TanyN3M0. This showed that there was a significant difference in the survival rate between the three groups (P＜0.0001).
In addition, following a comparison of the survival rate between the TanyN3cM0 group and stage IV based on the degree of the invasion to the gastric wall, there was a significant difference in the survival rate between T3N3cM0 and stage IV and that between 
The Number of Lymph Nodes That Were Dissected
The sixth edition of UICC TNM staging system declared that a pathological examination should be performed to make an accurate assessment of the degree of lymph node metastasis in more than and MAGIC Trial,(13) both of which were large-scale, randomized clinical studies conducted in America and Europe, the proportion of cases in whom a more extensive D2 lymph node dissection was performed was 10% and 41.4%, respectively. In addition, the proportion of cases in whom the D0 lymph node dissection, i.e., a less D1 lymph node dissection, was performed on 54% and 15.1%, respectively. According to ACTS-GC, a prospective, in randomized clinical study recently conducted in Japan, 99.8% of cases had a D2 lymph node dissection. This is contradictory to the above reports.
Of the total cases of gastric cancer surgery, which was performed at large-volume centers in Korea and the USA, the proportion of those in which less than 15 lymph nodes were dissected was 3% and 22%, respectively. A comparison of the survival rate of patients between the two hospitals during the same disease duration revealed the survival rates of patients with stage I/II/III to be significantly higher in Korea compared to USA. (14) One of the major causes of these results might be stage migration resulting from an insufficient lymph node dissection.
In cases in whom the dissection of more than 15 lymph nodes is an essential condition for the TNM staging, it might be impossible to determine the TNM stage in many patients from the USA and Europe. The current guidelines might have been loosened considering this in the seventh edition. In a future TNM staging system, the untoward effects called 'a lower standardization' can be prevented provided it is specified as the essential condition for TNM staging that more than 16 lymph nodes should be dissected.
The Proportion of Lymph Nodes with Metastasis
In the UICC and AJCC TNM Classification, the cuff-off point of the scope of lymph nodes with a metastasis has been revised continuously. To date, its gold standard has not been identified.
Given this background, the proportion of lymph nodes with a metastasis relative to the number of dissected lymph nodes was divided into several segments. Some suggest that it should be used as a tool for assessing the degree of lymph node metastasis. performed with a smaller number of dissected lymph nodes in the USA and Europe, it might also be a good method that can be used alternatively to the pre-existing TNM classification.
Constituents Forming the TNM Stage IV
In the sixth edition, the TNM stage IV included M0 and M1, which showed a significant difference in the survival rate.
Considering this, several authors reported that staging should be done in such a manner that stage IV should be differentiated into After classifying these cases into the neoadjuvant chemotherapy group and non-neoadjuvant chemotherapy group, the MST was found to be 13 months and 7 months, respectively. According to reports from the Queen Elizabeth Hospital in the UK, (29) in 207 cases of T3 and T4a, the positive rate and MST were 7.2% and 13 months, respectively. Indeed, a peritoneal washing cytology is not a diagnostic regimen that is commonly performed at most hospitals. Therefore, attempts were made to simply the concept of the Tcategory, which is one of the essential factors for the classification of TNM stage. To achieve these goals, it was declared that the classification system for esophageal cancer be followed in cases of EG junction carcinoma and the previous confusion was resolved accordingly. On the other hand, there is no evidence demonstrating the validity of the application of the classification system for esophageal cancer rather than stomach cancer. Besides, there are reports that the same T category should be applied to all cancers occurring at this site because the GI tract is formed of a single tubular structure. On the other hand, this would be problematic because the anatomical difference between the organs was not con- cm rule' proposed by Siewert but this was based on an obscure concept of the tumor epicenter. Accordingly in some cases, a gastric fundus tumor might also be considered as an esophageal cancer. Therefore, the current revision did not clarify the clinical issues that are well known regarding the EG junction carcinoma. Nevertheless, it did not discourage attempts to make a differentiation of an EG junction carcinoma from an esophageal or gastric cancer.
Conclusions
In the seventh edition of the UICC TNM staging, which has recently been revised, attempts were made to resolve the problems of previous editions of TNM staging. On the other hand, any noticeable matters have not been resolved. First of all, the N3 category was defined too extensively in the classification of lymph node metastasis. This achieved a simplification of the classification but it impaired the accuracy in predicting the prognosis in cases of progressive gastric cancer with a large number of lymph nodes with metastasis. Besides, it also did not clarify the minimum number of lymph nodes that should be dissected for appropriate TNM staging as shown previously. Therefore, it reduced the accuracy of TNM staging due to stage migration. Although it declared that it resolved the confusion of previous editions of TNM staging by specifying that the EG junction carcinoma should follow the classification system for esophageal cancer, it provided no clear evidence for this and did not resolve the previous issues. The edition also declared that positive cases to a peritoneal washing cytology should be considered a distant metastasis and then determined to be TNM stage IV. On the other hand, there are no standardized methods for this diagnostic regimen, which is not performed at many medical institutions, and deserves further consideration.
The most ideal TNM staging methods should be composed of simpler rules so that it may be used easily in a clinical setting.
Simultaneously, it should also guarantee the consistency between the cases corresponding to the same TNM stage and the differentiation between those corresponding to different TNM stages. This is quite challenging to surgeons. Further revisions of the TNM staging will be needed to contain both of these aspects to develop a harmonized classification.
